A randomized, controlled, prospective trial to evaluate the haemostatic effect of Lyostypt versus Surgicel in arterial bypass anastomosis: "COBBANA" trial

• Published in: Current controlled trials in cardiovascular medicine 2009-09, Vol.10 (1), p.91-91, Article 91
• Main Authors: Baumann, Petra, Schumacher, Hardy, Hüsing, Johannes, Luntz, Steffen, Knaebel, Hanns-Peter
• Format: Article
• Language: English
• Subjects: Analysis; Anticoagulants; Blood Vessel Prosthesis Implantation; Cellulose; Cellulose, Oxidized - pharmacology; Collagen; Collagen - pharmacology; Coronary artery bypass; Health aspects; Hemorrhage; Hemostatics - pharmacology; Humans; Informed consent; Methods; Mortality; Patients; Peripheral Vascular Diseases - surgery; Polytetrafluoroethylene; Prevention; Prospective Studies; Study Protocol; Surgery; Sutures
• ISSN: 1745-6215; 1745-6215
• DOI: 10.1186/1745-6215-10-91

The development of suture hole bleeding at peripheral arterial bypass anastomoses using PTFE graft prostheses is a common problem in peripheral vascular surgery. Traditionally the problem is managed by compression with surgical swabs and reversal heparin or by using several haemostatic device (e.g. different forms of collagen, oxidized cellulose, gelatine sponge, ethylcyanoacrylate glue or fibrin) with various success. Preclinical data suggest that the haemostatic effect of collagen is stronger than that of oxidized cellulose, but no direct clinical comparison of their hemostatic performance has been published so far. This randomized, controlled, prospective trial evaluates the haemostatic effect of Lyostypt versus Surgicel in arterial bypass anastomosis. 28 patients undergoing an elective peripheral vascular reconstruction due to peripheral vascular disease will be included. Suture hole bleeding occurring at the arterial bypass anastomosis using a PTFE prostheses will be stopped by the application of Lyostypt and/or Surgicel. The proximal anastomoses will be randomized intraoperatively. The patients will be allocated into 4 different treatment groups. Group1 Lyostypt distal/Surgicel proximal; Group 2: Lyostypt proximal/Surgicel distal; Group 3: Surgicel distal and proximal; Group 4: Lyostypt distal and proximal. Primary endpoint of the study is time to haemostasis. Secondary endpoints are the number of intraoperatively used haemostatic devices, postoperative mortality within 30 days as well as the intraoperative efficacy rating of the two devices evaluated by the surgeon. As a safety secondary parameter, the local and general complication occurring till 30 +/- 10 days postoperatively will also be analysed. After hospital discharge the investigator will examine the enrolled patients again at 30 days after surgery. The COBBANA trial aims to assess, whether the haemostatic effect of Lyostypt is superior to Surgicel in suture hole bleedings of arterial bypass anastomoses.